Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.

  • News

Executive Summary

Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market

You may also be interested in...



Drug Population, Risk Should Receive Greater Attention In R&D – Wyeth VP

Pharmaceutical R&D should focus more on targeting appropriate populations and risk assessment rather than immediate blockbuster potential, Wyeth VP-Project & Portfolio Management Richard Heaslip suggested

Drug Population, Risk Should Receive Greater Attention In R&D – Wyeth VP

Pharmaceutical R&D should focus more on targeting appropriate populations and risk assessment rather than immediate blockbuster potential, Wyeth VP-Project & Portfolio Management Richard Heaslip suggested

Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?

Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Mixed Support For ABPI's UK Price Scheme Proposals

FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development

‘Stop Fighting Us’ On Inspections, US FDA’s Califf Tells Industry; Foods Modernization Will Bring ‘Big Change’ To Drug Quality Systems

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

See All
UsernamePublicRestriction

Register

PS044816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By